CN105163735B - 用于治疗神经退行性疾病和其他疾病的组合物和方法 - Google Patents

用于治疗神经退行性疾病和其他疾病的组合物和方法 Download PDF

Info

Publication number
CN105163735B
CN105163735B CN201480019892.8A CN201480019892A CN105163735B CN 105163735 B CN105163735 B CN 105163735B CN 201480019892 A CN201480019892 A CN 201480019892A CN 105163735 B CN105163735 B CN 105163735B
Authority
CN
China
Prior art keywords
sulfasalazine
pharmaceutical composition
patient
formulated
certain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480019892.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105163735A (zh
Inventor
撒迪厄斯·克伦威尔·里德
马克·韦德·穆尔
道格拉斯·艾伦·洛伦茨
大卫·基思·莱昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glialogix Inc
Original Assignee
Glialogix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glialogix Inc filed Critical Glialogix Inc
Publication of CN105163735A publication Critical patent/CN105163735A/zh
Application granted granted Critical
Publication of CN105163735B publication Critical patent/CN105163735B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480019892.8A 2013-02-01 2014-01-31 用于治疗神经退行性疾病和其他疾病的组合物和方法 Expired - Fee Related CN105163735B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361759933P 2013-02-01 2013-02-01
US61/759,933 2013-02-01
US201361780340P 2013-03-13 2013-03-13
US61/780,340 2013-03-13
PCT/US2014/014290 WO2014121137A2 (en) 2013-02-01 2014-01-31 Compositions and methods for the treatment of neurodegenerative and other diseases

Publications (2)

Publication Number Publication Date
CN105163735A CN105163735A (zh) 2015-12-16
CN105163735B true CN105163735B (zh) 2018-12-11

Family

ID=50382538

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480019892.8A Expired - Fee Related CN105163735B (zh) 2013-02-01 2014-01-31 用于治疗神经退行性疾病和其他疾病的组合物和方法

Country Status (10)

Country Link
US (5) US9597339B2 (https=)
EP (1) EP2950797B1 (https=)
JP (2) JP6328146B2 (https=)
KR (1) KR20150139830A (https=)
CN (1) CN105163735B (https=)
AU (2) AU2014212109B2 (https=)
CA (1) CA2899032A1 (https=)
ES (1) ES2752021T3 (https=)
IL (1) IL240206A0 (https=)
WO (1) WO2014121137A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014212109B2 (en) * 2013-02-01 2018-05-31 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
KR102364840B1 (ko) 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
US20160199393A1 (en) * 2015-01-08 2016-07-14 China Medical University Methods of treating brain ischemia or hypoxia
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
AU2017257603A1 (en) * 2016-04-26 2018-11-22 Saint Louis University Highly selective adenosine A3 receptor subtype agonsists for the prevention and treatment of neurodegenerative disorders
TW201818933A (zh) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
US10473672B2 (en) * 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
US20230210871A1 (en) * 2017-10-12 2023-07-06 The Limited Company Research And Development Company "Medbiopharm" Use of sulfasalazine as an inhibitor of the formation of advanced glycation end products
WO2019102992A1 (ja) * 2017-11-21 2019-05-31 積水化学工業株式会社 皮膚外用剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1452490A (zh) * 2000-03-28 2003-10-29 纽若泰克 用柳氮磺吡啶干涉神经元的死亡的组合物和方法
CN101378751A (zh) * 2006-02-02 2009-03-04 诺瓦提斯公司 结节性硬化症治疗
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
CN102215868A (zh) * 2008-09-16 2011-10-12 弗·哈夫曼-拉罗切有限公司 用于治疗进行性多发性硬化的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
PL319600A1 (en) 1994-09-29 1997-08-18 Andaris Ltd Spray-dried microparticles as therapeutic carriers
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ITMI962356A1 (it) 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AU758351B2 (en) 1998-08-25 2003-03-20 Alkermes, Inc. Stable spray-dried protein formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CA2307278A1 (en) 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1824564A4 (en) 2004-10-27 2009-09-16 Uab Research Foundation METHOD FOR TREATING GLIOM
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20070053869A1 (en) 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
LT1983984T (lt) 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
US7964585B2 (en) 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
RU2434630C2 (ru) 2006-08-31 2011-11-27 Юранд, Инк. Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
PL2113254T3 (pl) * 2008-04-28 2013-01-31 Txcell Kompozycje do leczenia autoimmunologicznego stanu zapalnego
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
EP2811980A4 (en) 2012-01-31 2015-12-23 Cerulean Pharma Inc POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF
AU2014212109B2 (en) * 2013-02-01 2018-05-31 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
US20150182457A1 (en) 2013-12-31 2015-07-02 Ascendia Pharmaceuticals, Llc Pharmaceutical Compositions For Poorly Water-Soluble Compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1452490A (zh) * 2000-03-28 2003-10-29 纽若泰克 用柳氮磺吡啶干涉神经元的死亡的组合物和方法
CN101378751A (zh) * 2006-02-02 2009-03-04 诺瓦提斯公司 结节性硬化症治疗
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
CN102215868A (zh) * 2008-09-16 2011-10-12 弗·哈夫曼-拉罗切有限公司 用于治疗进行性多发性硬化的方法

Also Published As

Publication number Publication date
US9597339B2 (en) 2017-03-21
JP2018123159A (ja) 2018-08-09
US20190015431A1 (en) 2019-01-17
JP6328146B2 (ja) 2018-05-23
EP2950797A2 (en) 2015-12-09
CN105163735A (zh) 2015-12-16
AU2014212109A1 (en) 2015-08-06
WO2014121137A2 (en) 2014-08-07
US10398713B2 (en) 2019-09-03
JP2016507526A (ja) 2016-03-10
US9918997B2 (en) 2018-03-20
AU2014212109B2 (en) 2018-05-31
US20170079991A1 (en) 2017-03-23
KR20150139830A (ko) 2015-12-14
US20170165279A1 (en) 2017-06-15
ES2752021T3 (es) 2020-04-02
AU2018222921A1 (en) 2018-09-20
EP2950797B1 (en) 2019-09-11
IL240206A0 (en) 2015-09-24
US9974798B2 (en) 2018-05-22
WO2014121137A3 (en) 2014-11-27
CA2899032A1 (en) 2014-08-07
US9980978B2 (en) 2018-05-29
US20140221321A1 (en) 2014-08-07
US20170079990A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
CN105163735B (zh) 用于治疗神经退行性疾病和其他疾病的组合物和方法
JP7397239B2 (ja) インターロイキン－２３受容体のペプチド阻害剤の組成物
JP2023153783A (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
CN106999593A (zh) 用于纤维化治疗的赛尼克韦罗组合疗法
CN111278433A (zh) 尼拉帕尼制剂
EA037375B1 (ru) Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
CN117503775A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
JP2005505606A (ja) Ｃｏｘ−２インヒビターおよびアスピリンを含んでなる組合せ剤
JP2023544327A (ja) Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤
US20200009118A1 (en) Compositions and methods for the treatmentof neurodegenerative and other diseases
US20060013871A1 (en) Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
US20230141718A1 (en) Methods of treating glioblastoma
TW200948363A (en) Piperazine-based CCR5 antagonist tablet dosage form
CN111526875A (zh) 用于治疗骨关节炎疼痛的mPGES-1抑制剂
WO2024211881A1 (en) Rimegepant suspension
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
WO2026052068A1 (zh) 药物组合物的用途
WO2025218795A1 (zh) 一种药物组合物及其应用
WO2025108313A1 (zh) 包含egfr抑制剂的药物组合物
CN105407882A (zh) 包含呈阿戈美拉汀与有机酸的共晶体形式的阿戈美拉汀的药物制剂
HK1250932A1 (en) Formulations containing diacerein and methods of lowering blood levels of uric acid using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181211

Termination date: 20220131